ChinaDaily Briefs

Daily Brief China: Linklogis, Hong Kong Television Network, The United Laboratories International Holdings Limited, B&K Corporation, Lenovo and more

In today’s briefing:

  • Hang Seng Internet & IT Index (HSIII) Rebalance Preview: Three Adds/Deletes & Capping Changes
  • HKTV (1137 HK): HK$2.15 Share Buyback Is Unconditional
  • The United Laboratories Company Ltd (3933 HK) – A Sub Five PE Bargain!
  • Pre-IPO B&K Corporation – Valuation Performance Could Be Disappointing
  • Morning Views Asia: Lenovo


Hang Seng Internet & IT Index (HSIII) Rebalance Preview: Three Adds/Deletes & Capping Changes

By Brian Freitas

  • The review cutoff date for the September rebalance of the HSIII was 28 June. The changes will be announced on 16 August and become effective after the close 6 September.
  • There could be 3 changes to the index with some inclusions driven by potential addition to the Hang Seng Composite Index. That could lead to buying via Southbound Stock Connect.
  • Capping will result in passives buying Kuaishou Technology (1024 HK) and JD.com (9618 HK) while selling Meituan (3690 HK) and Tencent (700 HK).

HKTV (1137 HK): HK$2.15 Share Buyback Is Unconditional

By Arun George

  • The Hong Kong Television Network (1137 HK) vote on the share buyback for a maximum of 100.0m or 11.25% of outstanding shares at HK$2.15 was comfortably passed at the EGM.
  • The partial offer is designed to help the co-founders bypass the creeper rule and increase their grip on the shares. There is no minimum acceptance condition. 
  • While the IFA opines the offer is fair and reasonable, it is unattractive. A 100% minority participation rate implies a minimum proration of 20.74%. The offer closes on 23 July.  

The United Laboratories Company Ltd (3933 HK) – A Sub Five PE Bargain!

By Avien Pillay

  • At a 4.6 FPE, you would expect to find some real concerns, however there are no gremlins anywhere?  
  • What you are buying is an antibiotic developer and distributor who is performing better than expected, given that the antibiotic market is thriving.
  • The extensive pipeline including GLP-1 drugs is still at an early stage/midway through development, however at this valuation, you are probably not paying for it!

Pre-IPO B&K Corporation – Valuation Performance Could Be Disappointing

By Xinyao (Criss) Wang

  • The growth factor drug market is highly competitive. Many competing products have been on the market for many years with NRDL reimbursement coverage and also accumulated rich recognition from doctors/patients.
  • Even if Pro-101 is approved for market launch, B&K may have to reduce its price largely and invest heavily in market education/promotion. B&K’s commercialization capability still needs to be verified.
  • Valuation of B&K would be lower than peers. It is hard for B&K to receive expected valuation premium since its latest round of post investment valuation is already RMB3.3 billion.

Morning Views Asia: Lenovo

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars